Étiquette : CNS

OXELTIS

by jbertholdin Institutions, Service Providers & others

OXELTIS

About the company

Oxeltis is a medicinal chemistry services company created in 2010 in Montpellier, France, by former researchers from Idenix Pharmaceuticals (formerly MSD). The company has a small-scale custom synthesis business and hit and lead optimization services in various areas, such as antivirals, antibiotics, and anticancer compounds. Oxeltis’ scientific team comprises 21 experienced chemists with recognized expertise in specific areas of organic synthesis: heterocycles, macrocycles, nucleosides/nucleotides, phosphoramidites, iminosugars, modified sugars, oligosaccharides, and PROTACs. Oxeltis services includes also route scouting and up to 50-100g synthesis. Oxeltis works with European, Japanese, and North American start-ups, pharma companies, and research institutions.

About the solution

Oxeltis team is focused on speed of delivery, quality, and confidentiality of the services and collaborations it develops. Oxeltis has completed more than 35 projects with complex and multi-step synthetic chemistry for pharmaceutical and biotechnology companies, including five of the ten largest global pharmaceutical companies. Several drug candidates delivered to its customers are in clinical development.

Website
Key information

–  Therapeutic areas: Infectious diseases, antivirals, antibacterials, Oncology, Neurology, CNS

–  Based in: Montpellier (FRANCE)

–  Employees: 11 – 50

–  Created in: 2010

AGENT

by jbertholdin Medtech

AgenT

About the company

AgenT, founded in 2018, is on a mission to defeat Alzheimer’s by targeting the silent phase. Leveraging a groundbreaking multi-omics approach combined with A.I., they have identified new blood biomarkers deregulated from the earliest stages of the disease. Using this proprietary database, they have developed two blood tests, B-HEALED™ and B-AHEAD™, for early and precise detection during the pre-dementia stages, unlocking the future of precision medicine. Their innovation is crucial in the era of emerging treatments like Leqembi, enabling detection and treatment of Alzheimer’s before cognitive decline manifests.

By embracing precision medicine and expanding the biomarker toolkit, AgenT is positioning themselves for the next leap in Alzheimer’s treatment, ensuring patients receive the right therapy at the right time.

About the solution


Traditional Alzheimer’s tests detect brain amyloid levels—a risk factor, not a definitive diagnostic marker, leading to up to 25% false positives among mild cognitive impairment (MCI) patients. AgenT’s B-HEALED test dramatically reduces this false positive rate by two-thirds with its non-invasive, cost-effective, and scalable blood test, offering a breakthrough in Alzheimer’s diagnostics.

By accurately identifying MCI patients who can benefit from early intervention with disease-modifying treatments, their test ensures timely and precise therapy to slow Alzheimer’s progression effectively, without exposing non-Alzheimer’s patients to unnecessary drug side effects.

Website
Key information

–  Therapeutic areas: Alzheimer’s Disease, CNS

–  Based in: Paris (FRANCE)

–  Employees: 1-10

–  Created in: 2018

ARIANA PHARMACEUTICALS

by jbertholdin Digital Health

ARIANA PHARMACEUTICALS

About the company

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals.

With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

About the solution

Ariana Pharma has developed an explainable artificial intelligence platform which explores all possible biomarker associations, generating results that can be used directly to design clinical trials and accelerate drug development. Based on the mathematical theories of Formal Concept Analysis and Gallois lattices, the power of the KEM® platform lies in its ability to deliver explainable results from small cohorts. KEM® is also effective at managing contradictions and heterogeneous data, ensuring the identification of relevant and accurate hypotheses that meet the needs of precision medicine.

Website
Key information

–  Therapeutic areas: Oncology, CNS, Cardiometabolic, Immunology

–  Based in: Paris (FRANCE)

–  Employees: 11-50

–  Created in: 2003

SATT AxLR

by jbertholdin Institutions, Service Providers & others

SATT AxLR

About the company

SATT AxLR is a TTO based in south of France with a focus on innovative health projects from academic teams. SATT AxLR is funding early stages to allow project reaching a stage for technical transfer or company creation.

About the solution

SATT AxLR provide advice, contacts, funding to academic researchers (Universities, Hospitals, Public Instittutes,..) and generate intellectual property that is available for licensing.

Website
Key information

–  Therapeutic areas: Oncology, Immunology, CNS, Cardiology, Rare diseases, Obesity, Cell therapy, Medical Device

–  Based in: Montpellier (FRANCE)

–  Employees: 11 – 50

–  Created in: 2012

SYNCROSOME

by jbertholdin Institutions, Service Providers & others, Pharma

SYNCROSOME

About the company

SYNCROSOME is a CRO specialized in vivo efficacy studies with high expertise in cardiovascular, CNS, dermatology gastroenterology, metabolic disorders as well as respiratory fields for 23 years.

About the solution

They rely on a high expertise in animal models, high reactivity and high content data evaluation.

Website
Key information

–  Therapeutic areas: CNS, Cardiology, Gastrology, Dermatology, Respiratory and Metabolic disorders

–  Based in: Marseille (FRANCE)

–  Employees: 1 – 10

–  Created in: 2000

LYS THERAPEUTICS

by jbertholdin Biotech, Pharma

LYS THERAPEUTICS

About the company

Lys Therapeutics is a pioneering biotechnology company dedicated to addressing unmet medical needs in patients afflicted with neurovascular or neurodegenerative disorders through a revolutionary approach targeting blood-brain barrier (BBB) dysfunction.

Lys Therapeutics’ approach of targeting neuroinflammation to combat neurodegeneration represents a promising avenue in the quest for effective treatments for these debilitating disorders.

About the solution

In the pathophysiology of various neurological diseases such as stroke, multiple sclerosis, and Parkinson’s disease, hyperactivation of endothelial NMDA receptors (NMDAr) by overexpressed tissue plasminogen activator (tPA) leads to the degradation of tight junctions and subsequent BBB dysfunction. This process allows inflammatory cells and toxic molecules to migrate into the brain parenchyma, triggering severe neuroinflammation and excitotoxicity, which are primary contributors to neurodegeneration.

Lys Therapeutics’ lead compound, LYS241, is a first-in-class monoclonal antibody with a groundbreaking mechanism of action that effectively counters these pathological mechanisms. Specifically, LYS241 acts within blood vessels to prevent the binding of tPA to NMDAr, without interfering with the physiological function of NMDA receptors. By inhibiting this interaction, NMDA receptors can function normally, thereby halting downstream deleterious cellular pathways. As a result, tight junctions are reinstated, endothelial cells regain their healthy state, and BBB function is restored, shielding the brain from further neuroinflammatory and subsequent neurodegenerative cascades.

Website
Key information

–  Therapeutic areas: Neurology, CNS, Neurovascular diseases, Neurodegenerative disorders

–  Based in: Lyon and Caen (FRANCE)

–  Employees: 11 – 50

–  Created in: 2021

THERANEXUS

by jbertholdin Biotech, Pharma

THERANEXUS

About the company

Theranexus is a French biopharmaceutical company discovering and developing treatments to meet the needs of patients with rare neurological disorders.

About the solution

Their lead asset is an exclusive first liquid formulation of miglustat developed in Niemann Pick C and Batten diseases

Website
Key information

–  Therapeutic areas: Central nervous system (CNS)

–  Based in: Lyon (FRANCE)

–  Employees: 11 -50

– Created in: 2013

BDC

by jbertholdin Institutions, Service Providers & others

BIOTECH DEVELOPPEMENT CONSEILS

About the company

BDC is a global life sciences consulting firm that works with innovative medium-size companies to aggressively drive growth and capture extraordinary opportunities.
BDC helps to create value through technology-driven & long-term partnerships with industrial and pharma companies thanks to its extensive and powerful network. BDC benefits from the trust from industry higher management and from multiple proven competences in defining and applying strategies.

The management of BDC is composed of former executives from the industrial health sector and thanks to their expertise, BDC can assist start-ups and biotechs in almost every aspects of their “bio-business”: global strategy, business development (strategic alliances, portfolio management, licensing-in/out, distribution deals, …), discovery, R&D, legal aspects (contracts, intellectual property, litigation, …), to name a few.
Thanks to its team BDC can conduct business internationally and has offices in France, Israel, Switzerland, Singapore and Germany.

About the solution

BDC is specialized in corporate strategy, business development, assets valorization, technology transfer, fundraising, …

Website
Key information

–  Therapeutic areas: Oncology, Inflammation, CGT, AI, CNS, Metabolic diseases, Dermatology, Medical Devices, Diagnostics

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2002

KARLA THERAPEUTICS

by jbertholdin Biotech, Pharma

KARLA THERAPEUTICS

About the company

Karla is the first immuno-psychiatry company developing precision therapeutics to treat mental disorders (personalized medicine applied to psychiatry). We have a primary focus on schizophrenia and our immuno-centric approach has potential applications across multiple psychiatric diseases.

About the solution

Our approach stems from 10 years of research made at Queen Mary University of London.
We have evidence showing that our novel target – a protein that we call “imood” – is critically involved in T cell-mediated homeostatic regulation of brain functions.
We have demonstrated the T cell specificity of imood as well as its capabilities to modulate behavior in wt mice.
Circulating imood can be found in (healthy) human plasma and we have data showing that it is dysregulated in plasma, PBMCs and T cells from psychiatric patients.
We are developing anti-imood mAb as the first precision medicine therapeutic in psychiatry.

Website
Key information

–  Therapeutic areas: Neuropsychiatry, CNS disorders

–  Based in: Saint-Beauzire (FRANCE)

–  Employees: 1 – 10

– Created in: 2022

H.A.C PHARMA

by jbertholdin Biotech, Pharma

H.A.C PHARMA

About the company

H.A.C. Pharma is a European pharmaceutical company incorporated in 2007 in France. H.A.C. Pharma markets and promotes high therapeutic value drugs, especially in pathologies with reduced alternatives for the patient.

The company works with a network of trusted distributors in 6 European countries (Spain, Italy, Belgium, Austria, Switzerland and Portugal) and directly in France with its own sales force.

The company’s drugs are mainly promoted to specialists in hospital setup in the area of endocrinology, neuropsychiatry, gynecology, onco-hematology and gastroenterology.

About the solution

H.A.C. Pharma is your partner of choice to launch your medicines in Europe: from clinical assessment of medical needs through go-to-market strategy, early-access program and full registration, importation and distribution, to promotion to specialists.

Website
Key information

–  Therapeutic areas: Neurology and CNS, Endocrinology, Hemato-oncology, Autoimmune diseases, Cardiology, Gynecology

–  Based in: Caen (FRANCE)

–  Employees: 11 – 50

– Created in: 2007

CONTACT
Philippe BissayCEO

philippe.bissay@hacpharma.com